ATE196844T1 - Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten - Google Patents

Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten

Info

Publication number
ATE196844T1
ATE196844T1 AT97926722T AT97926722T ATE196844T1 AT E196844 T1 ATE196844 T1 AT E196844T1 AT 97926722 T AT97926722 T AT 97926722T AT 97926722 T AT97926722 T AT 97926722T AT E196844 T1 ATE196844 T1 AT E196844T1
Authority
AT
Austria
Prior art keywords
taxotere
cis
docosahexaenoic acid
compositions containing
containing conjugates
Prior art date
Application number
AT97926722T
Other languages
English (en)
Inventor
Matthews O Bradley
Victor E Shashoua
Nigel L Webb
Charles S Swindell
Original Assignee
Protarga Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protarga Inc filed Critical Protarga Inc
Application granted granted Critical
Publication of ATE196844T1 publication Critical patent/ATE196844T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT97926722T 1996-05-22 1997-05-22 Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten ATE196844T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65142996A 1996-05-22 1996-05-22
PCT/US1997/008866 WO1997044026A1 (en) 1996-05-22 1997-05-22 Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere

Publications (1)

Publication Number Publication Date
ATE196844T1 true ATE196844T1 (de) 2000-10-15

Family

ID=24612833

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926722T ATE196844T1 (de) 1996-05-22 1997-05-22 Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten

Country Status (9)

Country Link
US (1) US6080877A (de)
EP (1) EP0914116B1 (de)
JP (1) JP4172726B2 (de)
AT (1) ATE196844T1 (de)
CA (1) CA2255615C (de)
DE (1) DE69703294T2 (de)
DK (1) DK0914116T3 (de)
ES (1) ES2151277T3 (de)
WO (1) WO1997044026A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0870510A3 (de) * 1997-04-11 1999-09-15 Eli Lilly And Company Synergistische Zusammensetzung enthaltend Cryptophycinderivate und synergistische mikrotubuli Mitteln
US7288665B1 (en) * 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9804361D0 (en) * 1998-03-02 1998-04-22 Scotia Holdings Plc Cancer treatment
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6207660B1 (en) * 1998-06-05 2001-03-27 Jonathan L. Sessler Texaphyrin conjugates and uses thereof
GB9904386D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
KR20020000147A (ko) * 1999-03-09 2002-01-04 니겔 엘. 웹 지방산-항암제 결합체 및 그의 용도
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
CA2391502A1 (en) * 1999-11-15 2001-05-25 Pharma Mar S.A Aplidine treatment of cancers
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
CO5280224A1 (es) * 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
BR0104354A (pt) * 2000-02-02 2002-01-02 Univ Florida State Res Found Taxanos substituìdos com éster c10
US6649632B2 (en) 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
EP2275557A1 (de) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albuminfusionsproteine
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US6624317B1 (en) 2000-09-25 2003-09-23 The University Of North Carolina At Chapel Hill Taxoid conjugates as antimitotic and antitumor agents
BR0114604A (pt) * 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
JP2005500988A (ja) * 2001-03-23 2005-01-13 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪族アミン薬物複合体
US6825166B2 (en) 2001-03-23 2004-11-30 Tapestry Pharmaceuticals, Inc. Molecular conjugates for use in treatment of cancer
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
SG129990A1 (en) * 2001-08-01 2007-03-20 Univ Florida State Res Found C10 ester substituted taxanes
AU2002336206B2 (en) * 2001-10-19 2007-11-29 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
EP2990417A1 (de) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin-insulin-fusionsprotein
MXPA05001390A (es) 2002-08-02 2005-07-29 Immunogen Inc Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico.
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
WO2004080477A1 (en) * 2003-03-12 2004-09-23 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
WO2004103409A1 (ja) * 2003-05-26 2004-12-02 Hiroshi Maeda 抗腫瘍剤及びその製造方法
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
DE602004027936D1 (de) 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc Tocopherolmodifizierte therapeutische arzneimittelverbindung
CA2544128A1 (en) * 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
US7160919B2 (en) 2004-03-05 2007-01-09 Florida State University Research Foundation, Inc. C7 lactyloxy-substituted taxanes
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
EP1737472B1 (de) 2004-03-29 2014-08-13 University Of South Florida Wirksame Behandlung von Tumoren und Krebs mit Triciribin
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
WO2008021242A2 (en) * 2006-08-10 2008-02-21 The Research Foundation Of State University Of New York Fluorotaxoid-fatty acid conjugates and pharmaceutical compositions thereof
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8399420B2 (en) * 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
EP2276755A4 (de) 2008-03-31 2011-05-04 Univ Florida State Res Found C(10)-ethylester- und c(10)-cyclopropylester-substituierte taxane
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN109310771A (zh) * 2016-06-03 2019-02-05 埃维克辛公司 包含多不饱和酮与皮质甾类化合物的联合疗法
GB201609735D0 (en) * 2016-06-03 2016-07-20 Avexxin As Combination therapy
RS66574B1 (sr) 2016-07-29 2025-03-31 Janssen Pharmaceutica Nv Niraparib za upotrebu u postupku lečenja raka prostate
WO2018055062A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351831A (en) * 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
IT7927748A0 (it) * 1979-11-30 1979-11-30 Simes Derivati dell'acido 6,6'-diapopsi psicarotenedioico e relativi procedimenti di preparazione.
US4346085A (en) * 1980-02-29 1982-08-24 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
US4636494A (en) * 1981-01-30 1987-01-13 Massachusetts Institute Of Technology Process and composition for treating disorders by administering amphetamine and choline
JPS58177953A (ja) * 1982-04-13 1983-10-18 Eisai Co Ltd ポリプレニルカルボン酸アミドおよびその製造方法
JPS5925327A (ja) * 1982-07-31 1984-02-09 Hidematsu Hirai 抗腫瘍性複合体の製造方法
EP0133795B1 (de) * 1983-08-01 1989-01-18 THE McLEAN HOSPITAL CORPORATION Gaba-Ester und gaba-analoge Ester
US4550109A (en) * 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
US4684646A (en) * 1984-06-26 1987-08-04 Merck & Co., Inc. 2-acylaminomethyl-1,4-benzodiazepine derivatives as CCK-antagonists
US4554272A (en) * 1985-01-25 1985-11-19 Merck & Co., Inc. Substituted quinazolino-1,4-benzodiazepin-6,9-diones and their preparation
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5246726A (en) * 1986-03-21 1993-09-21 Efamol Ltd. Iron-containing composition and method for treatment of cancer
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
GB8716305D0 (en) * 1987-07-10 1987-08-19 Raychem Ltd Electrical wire
JPH01153629A (ja) * 1987-12-11 1989-06-15 Nippon Oil & Fats Co Ltd 制癌剤
JPH01203331A (ja) * 1988-02-05 1989-08-16 Rikagaku Kenkyusho 制癌剤
US4933324A (en) * 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US4939174A (en) * 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
JPH01287022A (ja) * 1988-05-12 1989-11-17 Nippon Oil & Fats Co Ltd 抗癌剤耐性克服剤
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
CH676909A5 (de) * 1988-12-23 1991-03-28 Nestle Sa
HU207287B (en) * 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
GB8918294D0 (en) * 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
IT1254515B (it) * 1992-03-06 1995-09-25 Indena Spa Tassani di interesse oncologico, loro metodo di preparazione ed uso
IT1254517B (it) * 1992-03-06 1995-09-25 Indena Spa 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
JPH0616548A (ja) * 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
US5453521A (en) * 1992-10-05 1995-09-26 Rhone-Poulenc Rorer S.A. Process for obtaining 10-deacetylbaccatin III
FR2696461B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5356928A (en) * 1992-11-06 1994-10-18 Hauser Chemical Research, Inc. Cytotoxic agents
FR2697841B1 (fr) * 1992-11-12 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2150470A1 (en) * 1992-11-30 1994-06-09 S.P.I. Synthetic Peptides Incorporated Polyunsaturated fatty acyl-peptide composition
FR2698871B1 (fr) * 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5336684A (en) * 1993-04-26 1994-08-09 Hauser Chemical Research, Inc. Oxidation products of cephalomannine
FR2707293A1 (fr) * 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712288B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2712289B1 (fr) * 1993-11-08 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
FR2721023B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux Taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2721928A1 (fr) * 1994-07-04 1996-01-05 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH0827010A (ja) * 1994-07-19 1996-01-30 Nichinichi Seiyaku Kk 制癌免疫療法剤
JPH08163991A (ja) * 1994-12-15 1996-06-25 Mitsui Petrochem Ind Ltd タキサン型ジテルペンの製造方法
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
GB9508823D0 (en) * 1995-05-01 1995-06-21 Scotia Holdings Plc Drug Derivatives
JPH0925231A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center 癌転移抑制剤
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes

Also Published As

Publication number Publication date
DE69703294D1 (de) 2000-11-16
CA2255615A1 (en) 1997-11-27
JP2000511188A (ja) 2000-08-29
WO1997044026A1 (en) 1997-11-27
DE69703294T2 (de) 2001-05-17
US6080877A (en) 2000-06-27
AU722912B2 (en) 2000-08-17
EP0914116A1 (de) 1999-05-12
DK0914116T3 (da) 2000-11-20
EP0914116B1 (de) 2000-10-11
ES2151277T3 (es) 2000-12-16
JP4172726B2 (ja) 2008-10-29
AU3142497A (en) 1997-12-09
CA2255615C (en) 2006-08-29

Similar Documents

Publication Publication Date Title
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
DE69708100D1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
DE69838177D1 (de) Androgensyntheseinhibitoren
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
ATE304350T1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DE69828175D1 (de) Zusammensetzung zur reduzierung von schlechten gerüchen enthaltend eine laccase
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE220795T1 (de) Rückgewinnung von taxanen aus koniferen
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
RU94042393A (ru) Галихондрины, родственные соединения и способ лечения опухоли у млекопитающих
DE69905170T2 (de) Thiazolopyrimidinderivate
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
DE69918413D1 (de) Auswahlverfahren von hla-g exprimierenden tumoren, die durch antikrebsmittel behandelbar sind, und deren verwendungen
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
SE9802937D0 (sv) Novel compounds
ATE381327T1 (de) Cethylmyristat und cetylpalmitat zurbehandlung von ekzemen und/oder psoriasis
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
BR9915955A (pt) Composição cosmética para cuidado com a pele, processo cosmético para tratar uma pele envelhecida e uso de 4- cromanona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee